$MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ร agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
William J. Sibold
CEO
528
Employees
$517.26
Current Price
$10.55B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 13 | $3,364,136.03 | 6,526 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 13 | $3,364,136.03 | 6,526 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 13 | $3,364,136.03 | 6,526 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 13 | $3,364,136.03 | 6,526 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 30 | $5,990,397.99 | 12,624 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 22, 2026 | Levy Richard S Director | Sale | 80 | $519.98 | $41,598.40 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 657 | $515.92 | $338,960.69 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 439 | $512.50 | $224,988.47 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 1,497 | $517.59 | $774,835.37 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 782 | $518.76 | $405,668.76 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 723 | $516.87 | $373,693.97 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 151 | $510.36 | $77,064.04 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 40 | $512.97 | $20,518.80 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 40 | $506.68 | $20,267.00 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 320 | $508.24 | $162,637.44 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 610 | $511.40 | $311,951.99 | View Details |
| May 22, 2026 | Levy Richard S Director | Sale | 343 | $514.67 | $176,531.50 | View Details |
| May 18, 2026 | Soergel David Chief Medical Officer | Sale | 844 | $515.90 | $435,419.60 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 646 | $431.94 | $279,033.24 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 40 | $425.08 | $17,003.20 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 420 | $426.86 | $179,282.80 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 80 | $427.85 | $34,227.60 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 160 | $429.00 | $68,639.20 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 40 | $429.58 | $17,183.20 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 120 | $430.90 | $51,708.40 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated$0.01
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: